Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Control of Myopia in Young Children Using H.O.P.E. Lenses Combined With 0.02% Atropine Eye Drops

NCT07846787 · tracked via the Priya Life Science China tracker
Sponsor
Phase
Not applicable
Started
2026-09-30
Last updated
2026-09-29

Condition(s) studied

Myopia

Investigational drug(s) / intervention(s)

High-order Phase Element Array Microstructure Design Lens (H.O.P.E.)0.02% Atropine Sulfate Eye Drops →

High-order Phase Element Array Microstructure Design Lens (H.O.P.E.): Wear the H.O.P.E. lens frame glasses and use the placebo. Use it once per night for both eyes.

0.02% Atropine Sulfate Eye Drops: Wear single-vision frame glasses and use 0.02% atropine sulfate eye drops twice a day, once at night for both eyes.

Study summary

A multicenter, prospective, intervention study on the control of myopia in young children using high-order phase element array microstructure lenses (H.O.P.E.) in combination with low-concentration atropine eye drops (0.02%)

Eligibility

Sex
ALL
Min age
6 Years
Max age
9 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age: 6-9 years old (6 years old but under 10 years old), gender not restricted; 2. Clinically diagnosed with bilateral myopia (after cycloplegia), refractive error within -6.00D \< SER ≤ -0.50D, astigmatism ≤ 1.50D, refractive anisometropia ≤ 1.50D (based on subjective refraction values); 3. Corrected visual acuity LogMAR ≤ 0.1; 4. Able to understand the research purpose, voluntarily participate, and the subject and his/her legal guardian sign the informed consent form. Exclusion Criteria: If a subject meets any of the following exclusion criteria, they will not be included in this study: 1. Those who have discontinued the use of atropine eye drops (due to glaucoma or a tendency towards glaucoma, or are allergic to scopolamine or the components of this product); 2. Those currently suffering from any of the following diseases that may affect vision or refractive errors, or ocular organic diseases: such as diseases causing damage to the lens like cataracts, glaucoma, macular degeneration, corneal diseases, uveitis, retinal detachment, severe vitreous opacity, acute/chronic keratitis, conjunctivitis, irregular cornea, keratoconus, manifest strabismus, fundus diseases, etc.; systemic diseases that may affect the eyes, such as immune system diseases, central nervous system diseases, Down syndrome, asthma, epilepsy, severe heart or lung function disorders, severe liver or kidney function impairments, etc.; 3. Those who have participated in other clinical trials or studies related to myopia control within 90 days before signing the informed consent form; 4. Those who have used myopia control products within 90 days before signing the informed consent form (such as near-axial lenses, low-concentration atropine eye drops, corneal reshaping lenses, red light, etc.); 5. Those who cannot wear glasses regularly or use the medication as required (such as having a significant difference in compliance); 6. During the screening period, the intraocular pressure of either eye is greater than 21 mmHg or less than 10 mmHg, or the intraocular pressure difference between both eyes is ≥ 5 mmHg; 7. There is a severe abnormality in the accommodative function (accommodative amplitude \< 8D); 8. Only one eye meets the inclusion criteria; 9. Other situations that the researcher deems unsuitable for participating in this study.

Primary outcome measure(s)

  • The final spherical equivalent refractive error (SER) measured by cycloplegic refraction combined with both automated and subjective refraction after 12 months of wearing glasses, compared with the baseline value. — From enrollment to the end of treatment at 12 months

Trial sites (1)

FacilityCityRegionStatus
Tianjin Medical University Eye Hospital Tianjin China
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07846787 on ClinicalTrials.gov ↗ ← All trials in China